Effect of cyclophosphamide combined with glucocorticoid on crescentic IgA nephropathy
Objective To investigate the effect of cyclophosphamide(CTX)combined with glucocorticoid on the efficacy and renal function in patients with crescentic IgA nephropathy(IgAN).Methods A total of 88 patients with crescentic IgAN ad-mitted to our hospital from January 2020 to January 2022 were selected and divided into a control group(44 cases,treated with glucocorticoids)and a study group(44 cases,treated with CTX combined with glucocorticoids)by the random number table method.The clinical data of the patients were collected and the clinical efficacy,renal function,and blood pressure of the two groups were compared.Results Compared with the control group,the total effective rate of the study group was obviously in-creased(P＜0.05).Before treatment,there were no significant differences in blood urea nitrogen(BUN),serum creatinine(SCr),glomerular filtration rate(GFR),24 h urinary protein quantitation(24 h UPRO),urinary red blood cell count and blood pressure between the two groups of crescentic IgAN patients(P＞0.05).After treatment,BUN[(9.75±1.34)mmol/L vs(15.53±3.02)mmol/L],Scr[(100.83±19.78)μmol/L vs(204.42±40.23)μmol/L],24 h UPRO[(0.83±0.16)g vs(1.93±0.47)g],urine red blood cell count[(42.85±8.82)× 104/mL vs(802.99±99.06)×104/mL]and blood pressure of crescentic IgAN patients in the study group were significantly decreased(P＜0.05),and GFR[(69.45±15.38)mL/min vs(37.79±9.05)mL/min]was significantly increased(P＜0.05).The total incidence of adverse reactions in the study group was not obviously different from that in the control group(P＞0.05).Conclusion CTX combined with glucocorticoids is effective in the treatment of crescentic IgAN,which can improve the renal function of patients,thereby re-ducing the risk of progressive end-stage renal disease(ESKD).This treatment method is safe and worthy of application.
CyclophosphamideGlucocorticoidCrescentIgA nephropathyRenal function
NETL
NSTL
万方数据
